LCMV gp33-41

LCMV gp33-41, the carboxyl-extended 11-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes[1].

Product Specifications

CAS Number

[151705-84-9]

UNSPSC

12352209

Target

Arenavirus

Type

Peptides

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/LCMV_gp33-41.html

Purity

98.16

Solubility

H2O : 12.5 mg/mL (ultrasonic)

Smiles

O=C(N[C@@H](C)C(N[C@@H](C(C)C)C(N[C@@H](CC1=CC=C(C=C1)O)C(N[C@@H](CC(N)=O)C(N[C@@H](CC2=CC=CC=C2)C(N[C@@H](C)C(N[C@@H]([C@H](O)C)C(N[C@@H](CCSC)C(O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCCCN)N

Molecular Formula

C48H73N11O13S

Molecular Weight

1044.22

References & Citations

[1]Gairin JE, et al. Optimal lymphocytic choriomeningitis virus sequences restricted by H-2Db major histocompatibility complex class I molecules and presented to cytotoxic T lymphocytes. J Virol. 1995 Apr;69 (4) :2297-305.|[2]Smyth M, et al., Characterization of CD8 T Cell-Mediated Mutations in the Immunodominant Epitope GP33-41 of Lymphocytic Choriomeningitis Virus. Front Immunol. 2021 Jun 14;12:638485.